IL121041A0 - Immunogenic compositions for induction of anti-tumor immunity - Google Patents

Immunogenic compositions for induction of anti-tumor immunity

Info

Publication number
IL121041A0
IL121041A0 IL12104197A IL12104197A IL121041A0 IL 121041 A0 IL121041 A0 IL 121041A0 IL 12104197 A IL12104197 A IL 12104197A IL 12104197 A IL12104197 A IL 12104197A IL 121041 A0 IL121041 A0 IL 121041A0
Authority
IL
Israel
Prior art keywords
induction
immunogenic compositions
tumor immunity
immunity
tumor
Prior art date
Application number
IL12104197A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL12104197A priority Critical patent/IL121041A0/xx
Publication of IL121041A0 publication Critical patent/IL121041A0/xx
Priority to PCT/IL1998/000266 priority patent/WO1998056416A1/en
Priority to IL13342598A priority patent/IL133425A/xx
Priority to AU76723/98A priority patent/AU7672398A/en
Priority to EP98924544A priority patent/EP0989861A1/en
Priority to US10/032,482 priority patent/US7118744B2/en
Priority to US11/129,359 priority patent/US7378092B2/en
Priority to US11/943,255 priority patent/US20090098116A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12104197A 1997-06-09 1997-06-09 Immunogenic compositions for induction of anti-tumor immunity IL121041A0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL12104197A IL121041A0 (en) 1997-06-09 1997-06-09 Immunogenic compositions for induction of anti-tumor immunity
PCT/IL1998/000266 WO1998056416A1 (en) 1997-06-09 1998-06-09 Immunogenic compositions for induction of anti-tumor immunity
IL13342598A IL133425A (en) 1997-06-09 1998-06-09 Immunogenic compositions for induction of anti-tumor immunity
AU76723/98A AU7672398A (en) 1997-06-09 1998-06-09 Immunogenic compositions for induction of anti-tumor immunity
EP98924544A EP0989861A1 (en) 1997-06-09 1998-06-09 Immunogenic compositions for induction of anti-tumor immunity
US10/032,482 US7118744B2 (en) 1997-06-09 2002-01-02 Immunogenic compositions for induction of anti-tumor immunity
US11/129,359 US7378092B2 (en) 1997-06-09 2005-05-16 Immunogenic compositions for induction of anti-tumor immunity
US11/943,255 US20090098116A1 (en) 1997-06-09 2007-11-20 Immunogenic compositions for induction of anti-tumor immunity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12104197A IL121041A0 (en) 1997-06-09 1997-06-09 Immunogenic compositions for induction of anti-tumor immunity

Publications (1)

Publication Number Publication Date
IL121041A0 true IL121041A0 (en) 1997-11-20

Family

ID=11070246

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12104197A IL121041A0 (en) 1997-06-09 1997-06-09 Immunogenic compositions for induction of anti-tumor immunity

Country Status (5)

Country Link
US (3) US7118744B2 (xx)
EP (1) EP0989861A1 (xx)
AU (1) AU7672398A (xx)
IL (1) IL121041A0 (xx)
WO (1) WO1998056416A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2354862A1 (en) * 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
CA2360382C (en) * 1999-01-13 2011-05-24 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Use of antibodies for the vaccination against cancer
AUPP932199A0 (en) * 1999-03-19 1999-04-15 St Vincent's Hospital Sydney Limited Anti-p53 antibodies
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
JP2004507459A (ja) * 1999-08-25 2004-03-11 アルタレックス　コーポレイション 免疫病態治療用組成物および方法
EP1088557A1 (en) * 1999-09-28 2001-04-04 Kevin More Plumley Immunisation against cancer with mutated p53
GR1003883B (el) * 2001-05-09 2002-05-09 Εμβολιο παρεμποδισης μεταστασεων καρκινικων ογκων
US7833734B2 (en) * 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
AU2003900767A0 (en) * 2003-02-21 2003-03-13 St Vincent's Hospital Sydney Limited Idiotypic vaccine
HUE024953T2 (en) 2004-08-23 2016-02-29 Yeda Res & Dev Peptide inhibitors to mediate stress responses
GB2429013C (en) 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
MX2009006471A (es) * 2006-12-14 2009-06-26 Schering Corp Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
US20240052056A9 (en) * 2012-03-30 2024-02-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CA3190470A1 (en) * 2020-08-28 2022-03-03 Robert Hromas Antibodies specific to ccl21 and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068177A (en) * 1983-12-28 1991-11-26 Scripps Clinic And Research Foundation Anti-idiotype antibodies induced by synthetic polypeptides
WO1992013970A1 (en) * 1991-02-01 1992-08-20 Oncogene Science, Inc. Immunoassay for detection of mutant p53 polypeptide in biological fluids
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
WO1993018792A1 (en) * 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity
CA2167303A1 (en) * 1993-07-20 1995-02-02 Michael Karin Regulation of transcription factor, nf-il6/lap
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
FR2736915B1 (fr) * 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
TW375759B (en) 1996-07-10 1999-12-01 Toray Industries Plasma display and preparation thereof
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation

Also Published As

Publication number Publication date
US7378092B2 (en) 2008-05-27
US20090098116A1 (en) 2009-04-16
AU7672398A (en) 1998-12-30
US20020197270A1 (en) 2002-12-26
US20050208065A1 (en) 2005-09-22
WO1998056416A1 (en) 1998-12-17
US7118744B2 (en) 2006-10-10
EP0989861A1 (en) 2000-04-05

Similar Documents

Publication Publication Date Title
IL121041A0 (en) Immunogenic compositions for induction of anti-tumor immunity
IL118004A0 (en) Vaccine compositions
IL117249A0 (en) Vaccine compositions
PL320584A1 (en) Oligomeric mixture of condensed alkyl alkoxysilanes
ZA978868B (en) Vaccine composition
IL137999A0 (en) Vaccine compositions
IL105161A0 (en) Vaccine compositions
IL209847A0 (en) Preparation of pharmaceutical compositions for processes for implenting selecive immune down regulation
GB9506039D0 (en) Underarm compositions
EP1015014A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS
ZA975751B (en) Underarm compositions
GB9616351D0 (en) Vaccine composition
GB9623233D0 (en) Vaccine composition
HU9600207D0 (en) Vaccine compositions
IL128806A0 (en) Compositions for immune therapy
GB9618426D0 (en) Underarm compositions
GB9521991D0 (en) Underarm compositions
GB9519772D0 (en) Preparing glass compositions
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
EP1064390A4 (en) IMPROVED ANTI-TUMOR IMMUNITY
GB9521990D0 (en) Underarm compositions
IL133425A (en) Immunogenic compositions for induction of anti-tumor immunity
GB9614618D0 (en) Vaccine compositions
GB9614188D0 (en) Ceramic compositions
HU9602318D0 (en) Adjuvant compositions